Primary graft dysfunction in lung transplantation: The role of CD26/dipeptidylpeptidase IV and vasoactive intestinal peptide

Transplantation

Volumn 87, Issue 8, 2009, Pages 1140-1146

  Zhai, Wei ^a,b   Jungraithmayr, Wolfgang ^a   De Meester, Ingrid ^c   Inci, Ilhan ^a   Augustyns, Koen ^c   Arni, Stephan ^a   Hillinger, Sven ^a   Scharpé, Simon ^c   Weder, Walter ^a   Korom, Stephan ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Dipeptidylpeptidase IV; Lung transplantation; Primary graft dysfunction; Vasoactive intestinal peptide

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; MYELOPEROXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VASOACTIVE INTESTINAL POLYPEPTIDE; HEPARIN; MELATONIN; PEROXIDASE;

AIRWAY PRESSURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GAS ANALYSIS; COLD ISCHEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HISTOLOGY; ISCHEMIA; LUNG ALVEOLUS MACROPHAGE; LUNG EDEMA; LUNG STRUCTURE; LUNG TRANSPLANTATION; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REPERFUSION INJURY; RESPIRATORY EPITHELIUM; RESPIRATORY FUNCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; FOLLOW UP; IMMUNOLOGY; ISOGRAFT; LEWIS RAT; METABOLISM; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PERFUSION; SURVIVAL;

ANIMALS; ANTIGENS, CD26; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEPARIN; LUNG TRANSPLANTATION; MELATONIN; PERFUSION; PEROXIDASE; RATS; RATS, INBRED LEW; REPERFUSION INJURY; SURVIVAL ANALYSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSPLANTATION, ISOGENEIC; VASOACTIVE INTESTINAL PEPTIDE;

EID: 65549123614     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819e04c3     Document Type: Article

References (33)

1. Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127: 161.
2. King RC, Binns OA, Rodriguez F, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69: 1681.
3. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart-lung transplantation report-2008. J Heart Lung Transplant 2008; 27: 957.
4. Christie JD, Carby M, Bag R, et al. ISHLT working group on primary lung graft dysfunction. Report of the ISHLT working group on primary lung graft dysfunction. II. Definition. A consensus statement of the international society for heart and lung transplantation. J Heart Lung Transplant 2005; 24: 1454.
5. Shargall Y, Guenther G, Ahya VN, et al. ISHLT working group on primary lung graft dysfunction. Report of the ISHLT working group on primary lung graft dysfunction. VI. Treatment. J Heart Lung Transplant 2005; 24: 1489.
6. Lambeir AM, Durinx C, Scharpe' S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209.
7. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998; 161: 55.
8. Simeoni L, Rufini A, Moretti T, et al. Human CD26 expression in transgenic mice affects murine T-cell populations and modifies their subset distribution. Hum Immunol 2002; 63: 719.
9. De Meester I, Korom S, Van Damme J, et al. CD26, let it cut or cut it down. Immunol Today 1999; 20: 367.
10. Jung FJ, Yang L, De Meester I, et al. CD26/dipeptidylpeptidase IVtargeted therapy of acute lung rejection in rats. J Heart Lung Transplant 2006; 25: 1109.
11. Zhai W, Cardell M, De Meester I, et al. Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia. J Heart Lung Transplant 2007; 26: 174.
12. Inci I, Inci D, Dutly A, et al. Melatonin attenuates posttransplant lung ischemia-reperfusion injury. Ann Thorac Surg 2002; 73: 220.
13. Zhai W, Ge J, Inci I, et al. Simplified rat lung transplantation by using a modified cuff technique. J Invest Surg 2008; 21: 33.
14. Graf R, Schiesser M, Lüssi A, et al. Coordinate regulation of secretory stress proteins (PSP/reg, PAP I, PAP II, and PAP III) in the rat exocrine pancreas during experimental acute pancreatitis. J Surg Res 2002; 105: 136.
15. Ichikawa S, Sreedharan SP, Owen RL, et al. Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung. Am J Physiol 1995; 268: L584.
16. Lasbury ME, Durant PJ, Bartlett MS, et al. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery. Clin Diagn Lab Immunol 2003; 10: 293.
17. Ghatei MA, Sheppard MN, O'Shaughnessy DJ, et al. Regulatory peptides in the mammalian respiratory tract. Endocrinology 1982; 111: 1248.
18. Said SI, Dickman KG. Pathways of inflammation and cell death in the lung: Modulation by vasoactive intestinal peptide. Regulatory Peptides 2000; 93: 21.
19. Groneberg DA, Rabe KF, Fischer A. Novel concepts of neuropeptidebased drug therapy: Vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 2006; 533: 182.
20. Lambeir AM, Durinx C, Proost P, et al. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 2001; 507: 327.
21. Zhu L, Tamvakopoulos C, Xie D, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003; 278: 22418.
22. Ng CS, Wan S, Arifi AA, et al. Inflammatory response to pulmonary ischemia-reperfusion injury. Surg Today 2006; 36: 205.
23. Zhang JS, Tan YR, Xiang Y, et al. Regulatory peptides modulate adhesion of polymorphonuclear leukocytes to bronchial epithelial cells through regulation of interleukins, ICAM-1 and NF-B/I-B. Acta Biochim Biophys Sin 2006; 38: 119.
24. Sergejeva S, Hoshino H, Yoshihara S, et al. A synthetic VIP peptide analogue inhibits neutrophil recruitment in rats airways in vivo. Regul Peptides 2004; 117: 149.
25. Li L, Luo ZQ, Zhou FW, et al. Effects of vasoactive intestinal peptide on pulmonary surfactants phospholipids synthesis in lung explants. Acta Pharmacol Sin 2004; 25: 1652.
26. Onoue S, Endo K, Ohmori Y, et al. Long-acting analogue of vasoactive intestinal peptide, (R15, 20, L17)-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke. Regul Pept 2004; 123: 193.
27. Palmer JB, Cuss FM, Barnes PJ. VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways. J Appl Physiol 1986; 61: 1322.
28. Groneberg DA, Springer J, Fischer A. Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 2001; 14: 391.
29. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984; 97: 304.
30. Allison RC, Kyle J, Adkins WK, et al. Effect of ischemia reperfusion or hypoxia reoxygenation on lung vascular permeability and resistance. J Appl Physiol 1990; 69: 597.
31. Loeckinger A, Schuette H, Walmrath D, et al. Protection against gas exchange abnormalities by pre-aerosolized PGE1, iloprost and nitroprusside in lung ischemia-reperfusion. Transplantation 2001; 71: 185.
32. Alessandrini F, Sasaki S, Said SI, et al. Enhancement of extended lung preservation with a vasoactive intestinal peptide-enriched University of Wisconsin solution. Transplantation 1995; 59: 1253.
33. Lambeir AM, Scharpe' S, De Meester I. DPP4 inhibitors for diabetes- what next? Biochem Pharmacol 2008; 76: 1637.